Live Chat ×
Skip to main content

Mutations in AML - Prognostic and Therapeutic Implications

Thank you

This live web event has ended. Thank you for attending.

Contributors

  • Courtney D. DiNardo, MD, MSCE

    Dr. DiNardo is a clinical researcher with a specialized focus on prognostication and personalized therapeutics for patients with myeloid malignancies. She has completed formal training in epidemiology and biostatistics, with a Master’s of Science in Clinical Epidemiology obtained in June 2012. Her thesis involved an analysis of isocitrate dehydrogenase (IDH) mutations, serum 2-hydroxyglutarate (2HG) levels, and patient outcomes in AML, performed in collaboration with the Eastern Cooperative Oncology Group (ECOG). Dr. DiNardo is the primary investigator of multiple novel IDH1 or IDH2-targeted therapeutic agents currently in clinical trials. Dr DiNardo is also involved in the clinical development of the BCL2-inhibitor venetoclax (ABT-199) for myeloid malignancies. She is leading the study of venetoclax in combination with hypomethylating agent therapy for the treatment of newly diagnosed elderly AML patients. In addition, Dr. DiNardo’s clinical and research focus pertaining to hereditary cancer predisposition syndromes has led to the development of the MD Anderson Hereditary Hematologic Malignancy Clinic, which now provides clinical and research-based evaluation of underlying cancer predispositions and hereditary cancer syndromes in leukemia patients. Degree-Granting Education 2012 University of Pennsylvania, Philadelphia, PA, USA, MS, Clinical Trials 2006 University of Michigan, Ann Arbor, MI, USA, MD, Medicine 2002 Emory University, Atlanta, GA, USA, BS, Biology

May 8, 2019
Wed 3:00 PM EDT

Duration 1H 0M

This live web event has ended.